Meng Lingzhong, Wu Zheng, Wang Yue, Lassman Charles, Busuttil Ronald W, Zhai Yuan, Kupiec-Weglinski Jerzy W
Division of Liver and Pancreas Transplantation, Department of Surgery, Dumont-UCLA Transplant Center, Los Angeles, CA 90095, USA.
Transplantation. 2008 May 15;85(9):1332-8. doi: 10.1097/TP.0b013e31816c4f2b.
Although CD154 costimulation blockade prolongs allograft survival in multiple transplantation models, the underlying immunological mechanisms remain to be elucidated.
We used a murine orthotopic kidney allograft (KTx) model to analyze the impact of CD154 blockade on trafficking and function of alloreactive T effector versus T regulatory cells. A single dose of MR1 Ab treatment at the time of KTx significantly improved the survival of Balb/c KTx in naïve C57BL/6 recipients (mean survival time >100 days vs. 52 days in controls; P<0.005), and improved graft histology, as evidenced by decreased lymphocyte infiltration and preservation of tissue architecture (days 6-8). In the early posttransplant phase, fluorescence-activated cell sorting analysis revealed preferential depression of T effector (CD8+CD25+) and relative enrichment of T-regulatory (CD4+ CD25+ CD152+) cells selectively in KTx. This pattern was further supported by intragraft gene expression analysis, which showed increased FoxP3/Tbet ratio and simultaneously decreased granzyme B/IFN-gamma levels in Ab-treated recipients. Additionally, MR1 Ab selectively up-regulated intragraft CCL17, but suppressed CXCL9/CCL5, in parallel with increased CCR4/CCR8 but unaltered CXCR3 expression.
These results provide evidence, at both cellular and molecular levels, that CD154 blockade in murine KTx recipients differentially targeted T-effector and T-regulatory cell subsets by regulating intragraft induction of chemokines targeting distinct T-cell subsets.
尽管共刺激分子CD154阻断在多种移植模型中可延长同种异体移植物存活时间,但其潜在的免疫机制仍有待阐明。
我们采用小鼠原位肾移植(KTx)模型,分析CD154阻断对同种异体反应性T效应细胞和T调节细胞的迁移及功能的影响。在肾移植时给予单次剂量的MR1抗体治疗,可显著提高Balb/c肾移植在未致敏的C57BL/6受体中的存活时间(平均存活时间>100天,而对照组为52天;P<0.005),并改善移植肾组织学,表现为淋巴细胞浸润减少和组织结构保存(第6 - 8天)。在移植后早期,荧光激活细胞分选分析显示,在肾移植中T效应细胞(CD8+CD25+)优先受到抑制,而T调节细胞(CD4+CD25+CD152+)相对富集。移植肾内基因表达分析进一步支持了这一模式,该分析显示,接受抗体治疗的受体中FoxP3/Tbet比值增加,同时颗粒酶B/干扰素-γ水平降低。此外,MR1抗体选择性上调移植肾内CCL17,但抑制CXCL9/CCL5,同时CCR4/CCR8增加,但CXCR3表达未改变。
这些结果在细胞和分子水平上均提供了证据,表明在小鼠肾移植受体中,CD154阻断通过调节移植肾内针对不同T细胞亚群的趋化因子诱导,对T效应细胞和T调节细胞亚群具有不同的靶向作用。